A first step in the gene therapy of tubulin glutamylation disorders
Open Access
- 21 October 2025
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 33 (11) , 5305-5306
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- AAV-based gene therapy ameliorates neurological deficits in a mouse model of childhood-onset neurodegeneration with cerebellar atrophyMolecular Therapy, 2025
- Tubulin glutamylation regulates axon guidance via the selective tuning of microtubule-severing enzymesThe EMBO Journal, 2024
- AAV-based in vivo gene therapy for neurological disordersNature Reviews Drug Discovery, 2023
- The Childhood-Onset Neurodegeneration with Cerebellar Atrophy (CONDCA) Disease Caused by AGTPBP1 Gene Mutations: The Purkinje Cell Degeneration Mouse as an Animal Model for the Study of this Human DiseaseBiomedicines, 2021
- Distinct roles of α‐ and β‐tubulin polyglutamylation in controlling axonal transport and in neurodegenerationThe EMBO Journal, 2021
- The tubulin code and its role in controlling microtubule properties and functionsNature Reviews Molecular Cell Biology, 2020
- Excessive tubulin polyglutamylation causes neurodegeneration and perturbs neuronal transportThe EMBO Journal, 2018
- Loss of tubulin deglutamylase CCP1 causes infantile‐onset neurodegenerationThe EMBO Journal, 2018
- Tubulin Posttranslational Modifications and Emerging Links to Human DiseaseCell, 2018
- Purkinje cell degeneration ( pcd ) Phenotypes Caused by Mutations in the Axotomy-Induced Gene, Nna1Science, 2002